IC
EPRX

Ikarian Capital’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Ikarian Capital’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.79M Buy
1,214,741
+604,741
+99% +$4.87M 0.71% 38
2025
Q4 		$4.61M Buy
+610,000
New +$3.76M 0.36% 66

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Ikarian Capital's EPRX Position: Q1 2026 in Review

Ikarian Capital increased its Eupraxia Pharmaceuticals (EPRX) stake by 99% in Q1 2026, buying an estimated $4.87M and bringing the position to 1,214,741 shares worth $8.79M. The position accounts for 0.71% of the portfolio, ranked #38.

Ikarian Capital first reported a position in EPRX in Q4 2025 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Ikarian Capital held 1,214,741 shares of Eupraxia Pharmaceuticals worth $8.79M as of Q1 2026.
  • Ikarian Capital bought 604,741 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $4.87M.
  • Eupraxia Pharmaceuticals made up 0.71% of Ikarian Capital's portfolio in Q1 2026, its #38 holding.
  • Ikarian Capital first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.